Reduction of PK11195 uptake observed in multiple sclerosis lesions after natalizumab initiation Academic Article uri icon

Overview

MeSH Major

  • Amyloidosis
  • Brain
  • Cognition Disorders
  • Diabetes Mellitus, Type 2

abstract

  • A reduction in PK11195 uptake was observed in both enhancing and chronic lesions after the start of natalizumab. PK11195 PET can be used as tool to assess the longitudinal change in MS lesions.

publication date

  • July 2017

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.msard.2017.04.008

PubMed ID

  • 28641769

Additional Document Info

start page

  • 27

end page

  • 33

volume

  • 15